COVID Protection After Transplant-Immunosuppression Reduction
- Conditions
- Kidney Transplant RecipientsLiver Transplant Recipients
- Interventions
- Biological: Pfizer-BioNTech COVID-19 Vaccine 2023-2024Biological: Moderna COVID-19 Vaccine 2023-2024Drug: SOC IS RegimenDrug: SOC IS Reduction
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2024-03-29
- Target Recruit Count
- 400
- Registration Number
- NCT05077254
- Locations
- 🇺🇸
University of Illinois Health, Chicago, Illinois, United States
🇺🇸Emory Healthcare, Atlanta, Georgia, United States
🇺🇸University of California, San Diego, San Diego, California, United States
An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
- Conditions
- Dengue
- Interventions
- Drug: JNJ-64281802 (sentinel high dose)Drug: PlaceboDrug: JNJ-64281802 (remaining high dose)Drug: JNJ-64281802 (medium/low dose)Drug: JNJ-64281802 (daily dosing regimen X)Drug: JNJ-64281802 (weekly dosing regimen Y1)Drug: JNJ-64281802 (weekly dosing regimen Z2)
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-11-13
- Target Recruit Count
- 54
- Registration Number
- NCT05048875
- Locations
- 🇺🇸
Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, United States
🇺🇸University of Vermont Medical Center (UVMMC), Clinical Research Center, Burlington, Vermont, United States
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-03-18
- Target Recruit Count
- 7
- Registration Number
- NCT05048238
- Locations
- 🇺🇸
University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology, Ann Arbor, Michigan, United States
🇺🇸University of Massachusetts Medical School, Worcester, Massachusetts, United States
Human Immune Response to Ixodes Scapularis Tick Bites
- Conditions
- Tick ResistanceTick-borne DiseasesLyme Disease
- Interventions
- Device: Xenodiagnosis TicksProcedure: skin biopsyProcedure: blood draw
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2024-10-03
- Target Recruit Count
- 60
- Registration Number
- NCT05036707
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine
- Conditions
- Influenza
- Interventions
- Other: IN PlaceboOther: IM PlaceboDrug: BPL-1357
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-03-21
- Target Recruit Count
- 45
- Registration Number
- NCT05027932
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
- Conditions
- Human Papillomavirus
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2025-01-03
- Target Recruit Count
- 850
- Registration Number
- NCT05026138
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Trial to Evaluate L9LS in Healthy Adults
- Conditions
- Malaria
- Interventions
- Drug: VRC-MALMAB0114-00-ABOther: Plasmodium falciparum (P. falciparum) sporozoite challenge
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-08-14
- Target Recruit Count
- 32
- Registration Number
- NCT05019729
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Carfilzomib and Belatacept for Desensitization
- Conditions
- Highly Sensitized Prospective Kidney Transplant Recipients
- Interventions
- Biological: carfilzomibBiological: belataceptProcedure: Bone marrow aspiration
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2024-01-26
- Target Recruit Count
- 15
- Registration Number
- NCT05017545
- Locations
- 🇺🇸
Duke Transplant Center, Duke University Medical Center, Durham, North Carolina, United States
Linezolid Dosing Strategies in Drug-Resistant TB
- Conditions
- Tuberculosis, Multidrug-ResistantTuberculosisTuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2024-10-08
- Target Recruit Count
- 132
- Registration Number
- NCT05007821
- Locations
- 🇧🇼
Gaborone CRS (Site ID: 12701), Gaborone, South-East District, Botswana
🇧🇷Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101), Rio De Janeiro, Brazil
🇭🇹GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS (Site ID: 31730), Port-au-Prince, Haiti
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
- Conditions
- Multiple Sclerosis (MS)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Pemphigus VulgarisPediatric SLEJuvenile Idiopathic Arthritis (JIA)Pediatric-Onset Multiple Sclerosis (POMS)Systemic Sclerosis (SSc)Juvenile Dermatomyositis (JDM)
- Interventions
- Biological: Moderna mRNA-1273Biological: BNT162b2Biological: Ad26.COV2.SBiological: Monovalent [B.1.351] CoV2 preS dTM-AS03Drug: Continue IS (MMF or MPA)Drug: Withhold IS (MMF or MPA)Drug: Continue IS (MTX)Drug: Withhold IS (MTX)Biological: Continue IS (B cell depletion therapy)Drug: Withhold IS (B cell depletion therapy)Biological: Moderna mRNA-1273, BivalentBiological: BNT162b2, Bivalent
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-04-10
- Target Recruit Count
- 257
- Registration Number
- NCT05000216
- Locations
- 🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States
🇺🇸Brigham & Women's Hospital: Department of Medicine, Rheumatology, Immunology, Boston, Massachusetts, United States
🇺🇸Benaroya Research Institute at Virginia Mason: Internal Medicine, Seattle, Washington, United States